Clinical Trial

Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to evaluate the efficacy and tolerability of Pavise Extracellular Matrix Restore (ECMR), compared with standard acute post-operative care, when used as the primary occlusive treatment immediately following ablative CO₂ and Er:YAG facial laser resurfacing to support wound healing.
Trial Details
NCT Number NCT07462533
Lead Sponsor Goldman, Butterwick, Fitzpatrick and Groff
Collaborators: Bai Biosciences
Conditions Skin Laxity
Enrollment 8 participants
Start Date 2026-03-20
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-10